Answer
Ezetimibe lowers systemic exposure to alirocumab by about 15% compared with alirocumab alone, but LDL-C reduction is maintained throughout the dosing interval when alirocumab is administered every two weeks.
Sources for this answer
- Praluent 75 mg solution for injection in pre filled penSANOFI · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated
Sources checked